Autopsy report · NCT00530361
An Efficacy and Safety Study for Nesiritide in Heart Failure Patients With Reduced Kidney Function Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass (CPB Pump or Heart Lung Machine)
Cause of deathFunding or business
“Study was withdrawn prior to patient dosing based on a business decision.”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 3
- Sponsor
- Scios, Inc.
- Sponsor type
- Industry
- Conditions
- Coronary Artery Bypass Surgery; Coronary Heart Disease; Coronary Artery Bypass Grafting; Cardiopulmonary Bypass; Ischemic Heart Disease; Heart Failure, Congestive
- Interventions
- Nesiritide
- Participants
- 0
Trials that died the same way
- Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
“This study was withdrawn due to a strategic business decision; no patients were enrolled.” - A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors
“Study was withdrawn due to scientific and business considerations.” - A Study of Glucose Control in Participants With Type 1 and Type 2 Diabetes
“Study was withdrawn prior to enrolment due to business decision.” - Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")
“due to business decision regarding the study drug.” - Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery
“This study was withdrawn for business reasons.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.